Đang chuẩn bị liên kết để tải về tài liệu:
Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: Analysis from a randomised, double-blind phase II study

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

A prospective, randomised phase II study demonstrated clinical benefit of axitinib dose titration in a subset of treatment-naïve patients treated with axitinib for metastatic renal cell carcinoma. This analysis evaluated patient baseline characteristics that may impact overall survival (OS) with axitinib dose titration. | Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration Analysis from a randomised double-blind phase II study

TÀI LIỆU LIÊN QUAN

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan

Treatment patterns and health outcomes in metastatic renal cell carcinoma patients treated with targeted systemic therapies in the UK

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: Results of matching-adjusted indirect comparison analyses

Prognostic value of performance status in metastatic renal cell carcinoma patients receiving tyrosine kinase inhibitors: A systematic review and meta-analysis

Prognostic value of CC-chemokine receptor seven expression in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: The largest multicenter retrospective analysis of survival and prognostic factors

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma

Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: Analysis from a randomised, double-blind phase II study

Ιmpact of sunitinib-induced hypothyroidism on survival of patients with metastatic renal cancer
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.